September 25, 2019

Santhera Shares Fall 2019 Community Update

Santhera has shared a community update on the company’s Duchenne drug development programs and their partnership with ReveraGen. Click here to download.

Learn More

August 27, 2019

Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone

A publication in the journal Neurology was released today describing efficacy studies of vamorolone, a treatment option being evaluated as a potentially safer alternative to corticosteroids, in people with Duchenne. PPMD is pleased to learn…

Learn More

August 14, 2019

Catabasis Shares August 2019 Newsletter

Catabasis shares the latest edition of their community newsletter, including an update on the Phase 3 PolarisDMD trial which is enrolling boys affected by Duchenne ages 4 to 7, any mutation type, that are not…

Learn More

April 5, 2019

Catabasis Shares March 2019 Newsletters

Catabasis shared the latest edition of their community newsletter (also available in Spanish), including an update on their currently recruiting Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Download the Catabasis newsletters: English Spanish

Learn More

February 19, 2019

Catabasis Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne

Catabasis Pharmaceuticals, Inc. shared additional clinical results from the MoveDMD trial of edasalonexent at the XVII International Conference on Duchenne and Becker Muscular Dystrophy in Rome, Italy this weekend. We are pleased to learn that in…

Learn More

February 12, 2019

WATCH: Vamorolone Clinical Trials in Duchenne – Webinar Recording

On January 30, 2019, ReveraGen joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the vamorolone drug development program for Duchenne, including results showing improved muscle function in…

Learn More

January 8, 2019

Meeting Update: Inflammation in Duchenne

Last month, PPMD convened a day and half meeting – Inflammation in Duchenne: Current and New Treatment Strategies – to bring academic and clinical researchers together to discuss advancements that could be made by treating…

Learn More

January 3, 2019

Catabasis Phase 3 PolarisDMD Trial for Edasalonexent Update & Additional Trial Sites Open for Enrollment

Catabasis Pharmaceuticals shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne. PolarisDMD clinical trial…

Learn More

November 20, 2018

Santhera Enters into Agreement to Acquire Option for Exclusive Sub-License of Vamorolone

PPMD has learned that Santhera Pharmaceuticals and Idorsia Ltd have entered into an agreement under which Santhera will acquire the option to exclusively in-license vamorolone, currently being developed by Reveragen. Idorsia currently holds the license…

Learn More

November 15, 2018

WATCH: PolarisDMD – Phase 3 Clinical Trial of Edasalonexent – Webinar Recording

PPMD and Catabasis as hosted a webinar on Wednesday, November 7 to discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy, which is enrolling boys ages 4 to 7 (up to…

Learn More